Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nolasiban
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Yuyuan Bioscience
Deal Size : $132.0 million
Deal Type : Termination
ObsEva Recovers Full Worldwide Rights on Nolasiban
Details : Under the termination of agreement with Yuyuan, ObsEva recovered full worldwide rights on OBE001 (nolasiban), a novel, oral oxytocin receptor antagonist being developed to improve pregnancy and live birth rates in women undergoing embryo transfer after i...
Product Name : OBE001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 13, 2023
Lead Product(s) : Nolasiban
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Yuyuan Bioscience
Deal Size : $132.0 million
Deal Type : Termination
Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : XOMA
Deal Size : $490.0 million
Deal Type : Acquisition
Details : Under the terms of the agreement, XOMA has acquired all rights to ebopiprant held by ObsEva, including the Organon/ObsEva license agreement and the IP associated with the asset.
Product Name : OBE022
Product Type : Other Small Molecule
Upfront Cash : $15.0 million
November 22, 2022
Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : XOMA
Deal Size : $490.0 million
Deal Type : Acquisition
Lead Product(s) : Nolasiban
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Yuyuan Bioscience
Deal Size : Inapplicable
Deal Type : Inapplicable
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
Details : Nolasiban (OBE001), an oral oxytocin receptor antagonist with the potential to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation. This increases the chance of successful pregnancy and ...
Product Name : OBE001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2022
Lead Product(s) : Nolasiban
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Yuyuan Bioscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Linzagolix,Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results demonstrated that OBE-2109 (linzagolix) has potential to balance safety, efficacy, and address wide-ranging symptoms of uterine fibroids also showed promise in delivering sustained clinical benefit.
Product Name : Yselty
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 05, 2022
Lead Product(s) : Linzagolix,Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Linzagolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy, for the Treatment of Uterine Fibroids.
Product Name : Yselty
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2022
Lead Product(s) : Linzagolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Linzagolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Theramex
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Yselty (Linzagolix) is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF.
Product Name : Yselty
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 17, 2022
Lead Product(s) : Linzagolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Theramex
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Linzagolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses
Details : Summary of data and key takeaway: At 12 weeks, once-daily treatment with Yselty (linzagolix 200 mg) with hormonal ABT significantly improved dysmenorrhea, non-menstrual pelvic pain, and other symptoms of endometriosis, including dyschezia and ability to ...
Product Name : Yselty
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2022
Lead Product(s) : Linzagolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Linzagolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Theramex
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : ObsEva has entered into a licensing agreement with Theramex to support the commercialization and market introduction of linzagolix in Europe. Theramex’s extensive women’s health commercial infrastructure includes a dedicated sales force of more than ...
Product Name : Yselty
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 25, 2022
Lead Product(s) : Linzagolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Theramex
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Linzagolix,Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Both DYS and NMPP showed rapid reductions compared to placebo (after 1 and 2 months of treatment), with continued reduction up to 6 months of treatment and with higher reductions with linzagolix, an oral GnRH antagonist, 200 mg + ABT compared to linzago...
Product Name : Yselty
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2022
Lead Product(s) : Linzagolix,Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Linzagolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
Details : Study on trial of Linzagolix investigated that efficacy and safety of two dosing regimens, 100mg once daily and 200mg once daily, alone or in combination with hormonal ABT for the treatment of heavy menstrual bleeding associated with uterine fibroids.
Product Name : Yselty
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 22, 2021
Lead Product(s) : Linzagolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable